LimmaTech Biologics: An Alternate Way to Generate Therapeutic Proteins

10 Most Promising BioTech Startups in Europe - 2020

From data-driven diagnostics to game-changing gene therapies, biotech is playing an important role in the various industries, including healthcare, agriculture, and food. As such, this domain is attracting unprecedented amount of investments from venture capital firms and technology companies. Leveraging modern technologies, biotech startups are bringing about new breakthroughs in a cost-effective manner through nimble business strategies and agile and efficient technologies.

Genome sequencing is gaining momentum in the biotech industry as it provides researchers with DNA screening techniques to find new genetic biomarkers. Additionally, braincomputer interfaces (BCIs) or brain-machine interfaces have progressed significantly in recent years. There are BCIs that aim to restore mobility in people who are paralyzed by spinal cord injury, stroke, or brain disease. Apart from BCIs, Optogenetics is a recently developed technique for controlling the activity of individual neurons. Apart from these, the development of exosomes in Cancer Nanomedicine and Immunotherapy has also boosted the biotech sector. Furthermore, advancements in neuroscience have seen the development of new techniques for designing, delivering, and reinforcing training. The neuroscience space continues to grow and expand within and outside the biotech industry. With the progress of technology, the biotech industry has seen startups entering the arena with innovative technology at their disposal.

In this edition, StartupCity brings to you top-performing biotech startups that are making waves in the biotech industry in Europe. The mentioned companies demonstrate high value by offering solutions and services that are aimed at solving the industry pain points and taking biotech innovation to the next level to better human life. These firms have exhibited vast knowledge and in-depth expertise in biotechnology.

We bring to you StartupCity’s “10 Most Promising BioTech Startups in Europe - 2020.”

10 Most Promising BioTech Startups in Europe - 2020

    Most Promising BioTech Startups in Europe

  • Cerebral vasospasm is a complication that arises after clipping surgery is performed to prevent further bleeding of an aneurysm.Graz-based BIT Pharma has adopted a revolutionary approach to overcome the blood-brain barrier in the delivery of voltage-gated calcium channel antagonists, which led to the pathbreaking innovation NicaPlant®. NicaPlant®, a calcium channel antagonist loaded system, is implanted into the basal cisterns in close contact to the proximal cerebrovascular system at the time of aneurysm clipping. NicaPlant® allows the slow tailored release in situ of the calcium blocker nicardipine at a constant concentration to the cerebral blood vessel wall over a period of about 14 days at the site of action, which prevents cerebral vasospasm.

  • A Dutch university spin-off company, IamFluidics provides proprietary and disruptive technology that uniquely enables the high-throughput production of uniform microparticles

  • LenioBio is a Düsseldorf-based organisation that develops efficient and sustainable technologies to disrupt the way medicines and food are produced for those in need, wherever they are. Besides producing proteins on demand at any location, the company reduces the time required to develop and market the medications. The company offers a cell-free production platform, ALiCE, which facilitates the large-scale production and processing of plant cells to obtain their cell-free extracts to produce protein. ALiCE, being an open system, helps find the right conditions for producing the protein that the customers are interested in

  • A clinical-stage biopharmaceutical company, LimmaTech, is developing a proprietary platform to control the structural complexity and heterogeneity that arises during the chemical modification of therapeutic proteins. The proprietary platform, CustomGlycanPlatform, regulates the therapeutic expression of glycans and develops monoclonal antibodies that maximise the ability of effector cells. With this innovative technology, the firm aims to help pharma companies offer better drugs at a lower cost and facilitate the treatment and prevention of life-threatening diseases

  • Algalife


    Algalife explores a holistic and sustainable development of new materials which positively affect both the environment and the human skin. It deals with relationships between biology, technology, man and nature, which are all intertwined to bring new sustainable solutions for the fashion industry. The company is also developing from the microorganism algae, which is renewable and healthy microorganism, new and innovative pigments and fibers that will dramatically change and reshape the fashion industry. The algae comes from a unique ecosystem and it's valuable substance as proteins, vitamins, anti-inflammatory and antioxidant, are released to the skin moisture when worn and offers nourishing and protection to our body and skin.

  • Biohope


    Biohope is a commercial stage biomedical company focused in the R&D, IP protection and regulatory clearance of PRECISION MEDICINE IVD tools, for chronic inflammatory conditions. Biohope has developed an IVD kit called Immunobiogram® to personalize drug treatment for patients with a renal transplant and rheumatoid arthritis. Immunobiogram® has shown positive results in our Clinical Trials and it is ready to go to market in 2020 through partners and licensees around the world. Biohope is an ideal Company to partner as they have a large, growing, profitable and unsatisfied market with clear advantages over competitors. They also have a breakthrough precision medicine product adding value to physicians, patients and payers.

  • Inorbit Therapeutics

    Inorbit Therapeutics

    Inorbit Therapeutics AB (InorbitTX) was founded in 2015. It is a privately owned virtual Drug Discovery and Development company based in the BioVentureHub in Mölndal, near Gothenburg, Sweden. The company focuses on small molecule drug discovery and development expertise on areas with a high unmet medical need and an excellent market perspective with a special interest for Non Alcoholic Steato Hepatitis (NASH). InorbitTX applies a unique groundbreaking chemotype to generate its potential new drugs. This chemotype is specifically designed to mitigate the risk for Drug Induced Liver Injury (DILI), a major cause for drug failure in late stages of development and even after approval and marketing.

  • LipoCoat


    LipoCoat BV is a spin-off company of the University of Twente (MESA+ nanotechnology institute). The LipoCoat revolutionary coating technology -which has its origin in 2010- will make any (bio)material surface non-thrombogenic, non-fouling and resistant towards surface pollution of micro-organisms and proteins. LipoCoat coatings can increase the performance, comfort and safety of medical devices or enhance research applications. In addition, they provide a service to tailor coating properties and functionality to meet peoples demand

  • myBioma


    The company makes advanced gut microbiome diagnostics publicly available by providing self-tests based on stool probes. Customers gain access to personalized reports to understand the cause of their problems and improve their well-being dependent on the their gut composition. Their vision is to offer state-of-the art advice to customers by continuously including the latest high-impact research into the analysis of the stool probes. They also provide high data security on Austrian servers and also increase the quality of life through individual recommendations

  • Oblique Therapeutics

    Oblique Therapeutics

    Oblique Therapeutics is a privately held Swedish biotech, developing innovative new medicines for severe diseases with a large unmet medical need focusing on pain, and advanced cancer. They use Abiprot, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises three in-house programs – two antibody candidates: aKRAS in advanced cancer, aTRPV1 in pain; and the small molecule OT-1096 in triple-negative breast cancer. In addition, they have two antibodies in collaboration with a large pharma company.